Section D: AstraZeneca COVID-19 Vaccine Section D: Summary of Changes Version
Date
Section
25
34.0
08/03/22
26
26.1 27
Summary of Changes
Updated language around prescribers to an ‘authorised prescriber’ Removed that AstraZeneca should not be exposed to direct sunlight. Clarified that a suitable covering is used when storing the drawn-up syringes. This ensures that used syringes are not put back with unused syringes Added “If it is unclear why the error has occurred contact IMAC for clinical guidance.” See above table (section A) for changes
Pathway to vaccination Section guidance This section is read in conjunction with Pfizer Vaccine section. This section provides additional operational guidance on the AstraZeneca COVID-19 Vaccine vaccination pathway, from booking and scheduling to vaccine preparation onto vaccine administration and observation.
Purpose The purpose of this section is guiding the vaccinating workforce to do the right thing and have the right resources and information available to provide a safe quality vaccination journey for every consumer. The key safety points are: •
Approved for use for people aged 18 years or over
•
AstraZeneca COVID-19 Vaccine does not need to be diluted on site
•
There are 10 doses per vial
The Ministry recommends vaccination to everyone of eligible age in Aotearoa New Zealand. The first line vaccine where there are no contraindications is the Pfizer vaccine. Version 34.0 Page 95
